Biosimilar market projected to reach $100B by 2027Market analysis shows significant growth potential in biosimilar sector driven by patent expirations.Market AnalysisBiosimilars
EU regulators signal faster reviews for interchangeable insulin biosimilarsAgencies are piloting streamlined pathways where interchangeability data is already established in member states.RegulatoryInsulinEU
Sandoz expands adalimumab biosimilar footprint in US channelsDeeper wholesaler agreements aim to improve pull-through as originator list prices remain elevated.LaunchImmunologyUS
Payers tighten step-edit rules for oncology biosimilar switchingCommercial plans are requiring longer originator trials before approving automatic substitution.AccessOncologyPayers
